Authors
Morgoshiia T.Sh., Kohanenko N.Yu., Ter-Ovanesov M.D., Syroezhin N.A.
St. Petersburg State Pediatric Medical University, St. Petersburg
Abstract
In the first part, it was noted that Barrett’s esophagus (PB) is a disease characterized by the replacement of a multilayer squamous epithelium with a metaplastic columnar epithelium. Taking into account modern ideas and accumulated clinical research data, the British Society of Gastroenterology in 2014 proposed a definition of Barrett’s esophagus based only on the description of metaplastic changes in the esophagus without taking into account their precancerous status. According to the authors, such a descriptive approach makes it possible not to focus on the traditional question of the risk of developing cancer in various types of metaplasia. However, after the diagnosis of Barrett’s esophagus, the risk of developing cancer should be determined individually in accordance with endoscopic, pathomorphological and molecular data. It is shown that, in accordance with the recommendations of the British Society of Gastroenterologists, Barrett’s esophagus refers to a pathological condition in which part of the normal flat epithelium of the mucosa of the distal esophagus is replaced by a metaplastic cylindrical epithelium, which is reliably determined by endoscopic examination (that is, larger than 1 cm) above the esophageal-gastric junction and morphologically verified. It follows from this definition that endoscopic and histological studies are the basis for the correct diagnosis of this pathological condition, and subsequent comparison of endoscopic and histological data allows us to determine the degree of changes in the mucous membrane and the risk of esophageal adenocarcinoma and, as a consequence, the tactics of treatment and management of patients.
Keywords: Barrett’s esophagus, gastroesophageal reflux disease, esophageal adenocarcinoma, endoscopy, dysplasia treatment, surgical treatment.
References
1. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7-42.
2. Birkmeyer JD, Stukel TA, Siewers AE et al . Surgical volume and operational mortality in the United States. N Engl J Med. 2003; 349: 2117-2127.
3. Konda VJ, Ross as, Ferguson MK, et al. Is the risk of developing concomitant invasive esophageal cancer overestimated in highly dispersed Barrett’s esophageal dysplasia? Clin Gastroenterol Hepatol. 2008; 6: 159-164.
4. Faith m, Stein HJ, and sivert Jr. Picture of the lymphogenic spread of ofbarrett’s cancer. World J Surg. 2003;27: 1052-1057.
5. Barrett N.R. Chronic peptic ulcer of the oesophagus and ‘oesophagitis’. Br J Surg. 1950; 38: 175-182.
6. Allison PR, Johnstone AS. The oesophagus lined with gastric mucous membrane. Thorax. 1953; 8: 87-101.
7. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery. 1957; 41: 881-894.
8. Kandel P, Wallace MB. The Role of Adjunct Imaging in Endoscopic Detection of Dysplasia in Barrett’sEsophagus. Gastrointest Endosc Clin N Am. 2017; 27: 423-446. doi: 10.1016/j.giec.2017.02.007.
9. Naveed M, Dunbar KB. Endoscopic imaging of Barrett’s esophagus. World J Gastrointest Endosc 2016; 8: 259-266. doi: 10.4253/wjge.v8.i5.259.
10. Phoa KN, et al. Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia. The Journal of the American Medical Association. 2014; 311(12): 1209-1217. doi: 10.1001/jama.2014.2511.
11. Melhado R, Alderson D, Tucker O. The Changing Face of Esophageal Cancer. Cancers. 2010; 2: 1379-1404.
12. Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC,Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C. Cost Effectiveness of ScreeningPatients With Gastroesophageal Reflux Disease for Barrett’s Esophagus With a Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol. 2017; 15: 1397-1404.e7. doi:10.1016/j.cgh.2017.02.017.
13. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. The American Journal of Gastroenterology. 2016; 111(1): 30-50. doi: 10.1038/ajg.2015.322.
14. Fock KM, Poh CH. Gastroesophageal reflux disease. J. Gastroenterol. 2010; 45(8): 808-815. doi: 10.1007/s00535-010-0274-9.
15. Gora MJ, et al. Tethered capsule endomicroscopy for microscopic imaging of the esophagus, stomach,and duodenum without sedation in humans (with video). Gastrointest Endosc. 2018; 88: 830-840.
16. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett’s esophagus. N Engl J Med. 1976; 295: 476-480.
17. Kilgore SP, Ormsby AH, Gramlich TL. The gastric cardia: fact or fiction? Am J Gastroenterology. 2000; 95: 921-924.
18. Quiglet EMM. The gastroesophageal junction revision: Perspectives in GERD. World Gastroenterology News. 2000; 5(2): 25-28.
19. Hayward J. The lower end of the esophagus. Thorax. 1961;16: 36-41.
20. Hamilton SR, Smith RRL, Cameron JL. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol. 1998; 19: 942-948.
21. Sharma P, Morales TG, Sampliner RE. Short segment Barrett’s esophagus — the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol. 1998; 93: 1033-1036.
22. Clark GW, Smyrk TC, Burdiles P, et al. Is Barrett’s metaplasia the source of adenocarcinoma of the cardia? Arch Surg. 1994; 129: 609-614.
23. Hirota W, Loughney T, Lazas D, et al. Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophago-gastric junction: prevalence and clinical data. Gastroenterology. 1999; 116: 277-285.
24. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996; 110: 614-621.
25. Stein HJ. and panel of experts: Esophageal cancer: Screening and surveillance. Dis Esoph’9.. 1996; 1: 3-19.
26. Reid BJ, Blount PL, Rubin CE, et al. Flow cytometric and histologic progression to malignancy in Barrett’s esophagus prospective endoscopic surveillance of a cohort. Gastroenterology. 1992; 102: 1212-1219.
27. Schnell TG, Sontag SJ, Chejfec G. Adenocarcinoma arising in tongues or short segments of Barrett’s esophagus. DigDis Sci. 1992; 37: 137-143.
28. Duits LC, et al. Abiomarker panel predicts progression of Barrett’s esophagus to esophageal adenocarcinoma. Dis Esophagus. 2019; 32. doi: 10.1093/dote/doy102.
29. Konda VJA, Souza RF. Biomarkers of Barrett’s Esophagus: From the Laboratory to Clinical Practice. DigDis Sci. 2018; 63: 2070-2080. doi: 10.1007/s10620-018-5088-2.
30. Vakil N, van Zanten S, Kahrilas P, Dent J, Jones R. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol. 2006; 101(8): 1900-1920.
31. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. The New England Journal of Medicine. 1999; 340(11): 825-831.
32. Duits LC, Phoa KN, Curvers WL, Ten Kate FJ, Meijer GA, Seldenrijk CA. Offerhaus Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015; 64(5): 700-706. doi:10.1136/gutjnl-2014-307278.
33. Ter-Ovanesov M.D. Faktory prognoza hirurgicheskogo lecheniya raka proksimal’nogo otdela zheludka. Avtoreferat dis. … dokt. med. nauk. M., 2007. 52 s. (In Russ).
34. Spechler S, Sharma P, Souza R, et al. American Gastroenterological Association Medical Position Statement on the Management of Barrett’s Esophagus. Gastroenterology. 2011; 140: 1084-1091.
35. ASGE Technology Committee. Thosani N, Abu Dayyeh BK, Sharma P, Aslanian HR, Enestvedt BK, Komanduri S, Manfredi M, Navaneethan U, Maple JT, Pannala R, Parsi MA, Smith ZL, Sullivan SA, Banerjee S. ASGE Technology Committee systematic review and meta-analysis assessing the ASGE Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for adopting real-timeimaging-assisted endoscopic targeted biopsy during endoscopic surveillance of Barrett’s esophagus. Gastrointest Endosc. 2016; 83: 684-98.e7. doi: 10.1016/j.gie.2016.01.007.
36. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinomaamong patients with Barrett’s esophagus. N Engl J Med. 2011; 365: 1375-1383. doi:10.1056/NEJMoa1103042.
37. Bremner CG. Barrett’s esophagus. In DeMeester TR, Matthews HR. (eds): International Trends in General Thoracic Surgery. 1987; 3: 227-244.
38. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophago-gastric junction and Barrett’s esophagus. Gastroenterology. 1995; 109: 1541-1546.
39. Hamilton SR, Smith RRL, Cameron JL. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol. 1998; 19: 942-948.
40. Spechler SJ, Sperber H, Doos WG, et al. The prevalence of Barrett’s esophagus in patients with chronic peptic esophageal strictures. Dig Dis Sci. 1983; 28: 769-774.
41. Whiteman DC, Appleyard M, Bahin FF, Bobryshev YV, Bourke MJ, Brown I, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol. 2015; 30(5): 804–820.
42. Tytgat GNJ, et al. What are the endoscopic criteria for diagnosing columnar metaplasia? The Esophageal Mucosa. Amsterdam. Elsevier. 1994: 795-798.
43. Phoa KN, et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentrestudy (EURO-II). Gut. 2016; 65(4): 555-562. doi:10.1136/gutjnl-2015-309298.
44.Weusten B, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2017; 49(2): 191-198. doi:10.1055/s-0042-122140.
45. Barret M, Belghazi K, Weusten BL, Bergman JJ, Pouw RE. Single-session endoscopic resection and focal radiofrequency ablation for short-segment Barrett’s esophaguswith early neoplasia. Gastrointestinal Endoscopy. 2016; 84(1): 29-36. doi:10.1016/j.gie.2015.12.034.
46. di Pietro M., Fitzgerald R. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett’s oesophagus with low-grade dysplasia. Gut, 2017; 67(2): 392-393.
47. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and mаnagement of Barrett’s esophagus. Am J Gastroenterol. 2016; 111(1): 30-50.
